Kammler 2021-08-04
Public Declaration of Interests and Confidentiality Undertaking of European Medicines Agency (EMA), Scientific Committee members and experts
Public declaration of interests
I, Hans-Jürgen Kammler Organisation/Company: Federal Institute for Drugs and Medical Devices Country: Germany do hereby declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical industry are those listed below:
2.1 Employment
No interest declared
2.2 Consultancy
Period Company Products Therapeutic Indication 03/2019-03/2020 Almirall Finasteride solution Androgenetic Alopecia
03/2019-06/2019 Almirall Terbinafin nail lacquer Onchomycosis
2.3 Strategic advisory role
No interest declared
2.4 Financial interests
No interest declared
2.5 Principal investigator Period Company Products Therapeutic Indication
07/2016-07/2017 Dr. Reddy's Laboratories, Ltd DFD-03 Lotion Acne vulgaris
11/2017-06/2019 Eli Lilly and Company Baricitinib Atopic Dermatitis
Classified as public by the European Medicines Agency
DOI Form Version-number: 4 Kammler 2021-08-04 2
04/2018-06/2020 Eli Lilly and Company Baricitinib Atopic Dermatitis
02/2018-09/2019 LEO Pharma A/S Tralokinumab Atopic Dermatitis
06/2018-12/2019 Afyx Therapeutics A/S Clobetasol Propionate Oral Lichen planus
07/2018-07/2019 Asana BioSciences ASN002 Atopic Dermatitis
11/2018-06/2020 LEO Pharma A/S Tralokinumab Atopic Dermatitis
11/2018-12/2019 AnaptysBio Inc ANB020 Atopic Dermatitis
01/2019-12/2019 Galapagos N.V. MOR106 Atopic Dermatitis
06/2018-02/2020 Menlo Therapeutics Inc Serlopitant Prurigo nodularis
06/2018-02/2020 Menlo Therapeutics Inc Serlopitant Pruritus
10/2018-06/2020 Pfizer Inc PF-04965842 Atopic Dermatitis
02/2019-06/2020 Pfizer Inc PF-04965842 Atopic Dermatitis
05/2019-06/2020 Pfizer Inc Abrocitinib Atopic Dermatitis
09/2018-06/2020 AbbVie Deutschland GmbH Upadacitinib Atopic Dermatitis
10/2018-06/2020 AbbVie Deutschland GmbH Upadacitinib Atopic Dermatitis
03/2019-06/2020 Pfizer Inc Crisaborole Atopic Dermatitis
08/2019-04/2020 Pfizer Inc PF-04965842 Atopic Dermatitis
2.6 Investigator
Period Company Products Therapeutic Indication
01/2014-05/2018 Regeneron Pharmaceuticals Inc Dupilumab Atopic Dermatitis
08/2012-06/2018 LETI Pharma GmbH Depigoid Birch 5000 Birch pollen allergy
06/2013-08/2018 Sun Pharma Global FZE Tildrakizumab Plaque Psoriasis
04/2014-02/2018 LEO Pharma A/S Calcipotriol/Betamethasone Psoriasis dipropionat
10/2014-06/2020 Janssen-Cilag International N.V. Guselkumab Plaque Psoriasis
12/2015-11/2017 Eli Lilly & Company Ltd Ixekizumab Plaque Psoriasis
02/2016-01/2018 Novartis Pharma GmbH Secukinumab Plaque Psoriasis
04/2016-12/2017 Merck KGaA MSB11022 Plaque Psoriasis
05/2016-08/2017 Boehringer Ingelheim Pharma GmbH Risankizumab Plaque Psoriasis
12/2015-12/2018 Novartis Pharma Services AG Secukinumab Plaque Psoriasis
08/2016-07/2019 Celgene Corporation Apremilast Plaque Psoriasis
01/2017-06/2018 GlaxoSmithKline GSK2646264 Cutaneous Lupus erythematosus
04/2017-12/2018 AbbVie Deutschland GmbH Risankizumab Plaque Psoriasis
05/2017-06/2020 Janssen-Cilag International N.V. Ustekinumab Plaque Psoriasis
05/2017-12/2019 Janssen-Cilag International N.V. Guselkumab Plaque Psoriasis
06/2017-11/2017 Dermtreat ApS Rivelin Patch Oral Lichen planus
06/2017-12/2018 AbbVie Deutschland GmbH Risankizumab Plaque Psoriasis
10/2017-05/2019 Galderma R&D, SNC Nemolizumab Prurigo nodularis
10/2017-05/2019 LEO Pharma A/S Brodalumab Psoriasis vulgaris
Classified as public by the European Medicines Agency
DOI Form Version-number: 4 Kammler 2021-08-04 3
02/2018-06/2020 Novartis Pharma GmbH Secukinumab Plaque Psoriasis
03/2018-02/2020 UCB Biopharma SPRL Bimekizumab Plaque Psoriasis
03/2018-12/2019 UCB Biopharma SPRL Bimekizumab Plaque Psoriasis
03/2018-08/2019 Prof. Reich (IIT) Apremilast Palmoplantar Pustulosis
01/2019-06/2020 Janssen-Cilag International NV Guselkumab Plaque Psoriasis
09/2018-01/2020 Novartis Pharma AG Secukinumab Plaque Psoriasis
09/2018-06/2020 Janssen-Cilag International NV Guselkumab Psoriasis
09/2019-06/2020 UCB Biopharma SRL Bimekizumab Plaque Psoriasis
04/2019-06/2020 Celgene Corporation Apremilast Genital Psoriasis
07/2019-06/2020 RWFU Bonn (IIT) Guselkumab Palmoplantar Pustulosis
08/2019-06/2020 Incyte Corporation Ruloxitinib Atopic Dermatitis
09/2019-06/2020 Pfizer Inc PF-06700841 Atopic Dermatitis
2.7 Grant / Funding to organisation /institution
No interest declared
2.8 Close family member interest
No interest declared
2.9 Repurposing of a medicinal product
No interest declared
2.10 Any other interests or facts No interest declared
2.11 Committee for Advanced Therapies (CAT) member or alternate Not a CAT member or alternate
CONFIDENTIALITY UNDERTAKING
In view of the following definitions: "EMA Activities" encompass any meeting (including meeting preparation and follow-up, associated discussion or any other related activity) of the European Medicines Agency's Management Board, Committees, Working Parties, Expert Groups, or any other such meeting; work as an expert on assessments; work as an expert on guidance development. "Confidential Information" means all information, facts, data and any other matters of which I acquire knowledge, either directly or indirectly, as a result of my EMA Activities. "Confidential Documents" mean all drafts, preparatory information, documents and any other material, together with any information contained therein, to which I have access, either directly or indirectly, as a result of my participation in
Classified as public by the European Medicines Agency
DOI Form Version-number: 4 Kammler 2021-08-04 4
EMA Activities. Furthermore, any records or notes made by me relating to Confidential Information or Confidential Documents shall be treated as Confidential Documents. I understand that I may be invited to participate either directly or indirectly in certain EMA activities and hereby undertake:
• To treat all Confidential Information and Confidential Documents under conditions of strict confidentiality as long as the information or document has not been made public/is not in the public domain.
• Not to disclose (or authorise any other person to disclose) in any way to any third party any Confidential Information or Confidential Document.
• Not to use (or authorise any other person to use) any Confidential Information or Confidential Document other than for the purposes of my work in connection with EMA activities.
• To dispose of Confidential Documents as confidential material as soon as I have no further use for them.
• When expressing views to clearly indicate that the views are my own if acting in my own capacity or those of the EMA, Committee, Working Party, Expert Group or other group if acting on behalf that group.
• Not to disclose any commercially confidential information. This undertaking shall not be limited in time, but shall not apply to any document or information that I can reasonably prove was known to me before the date of this undertaking or which becomes public knowledge other than as a result of a breach of any of the above undertakings. I confirm the information declared on this form is accurate to the best of my knowledge and I acknowledge that my information will be stored electronically and published on the EMA website.
Full Name: Hans-Jürgen Kammler Date: 2021-08-04
For Definitions of activities etc, refer to Policy on Handling of competing interests / Electronic DOI template
Classified as public by the European Medicines Agency
DOI Form Version-number: 4